View Future GrowthHelix BioPharma 過去の業績過去 基準チェック /06Helix BioPharma は平均年間 6% の収益成長を遂げていますが、Biotechs 業界では年間 収益成長率 となっています。33.8% です。主要情報6.02%収益成長率23.03%EPS成長率Biotechs 業界の成長17.04%収益成長率n/a株主資本利益率-27.32%ネット・マージンn/a前回の決算情報31 Jan 2026最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • Nov 24Helix BioPharma Corp., Annual General Meeting, Jan 30, 2026Helix BioPharma Corp., Annual General Meeting, Jan 30, 2026.お知らせ • Aug 23Helix BioPharma Corp. announced that it has received CAD 1.66675 million in fundingHelix BioPharma Corp. announced that it has closed non-brokered private placement to issue 2,222,333 common shares at a price of CAD 0.75 for gross proceeds of CAD 1,666,749.75 on August 22, 2025. The Offering is subject to final approval of the Toronto Stock Exchange, and the Common Shares are subject to a hold period of four months and one day expiring on December 23, 2025, in accordance with applicable securities laws. In connection with the closing of the Offering, the Company will pay finders’ fees to certain eligible finders.お知らせ • May 21Helix BioPharma Corp. (TSX:HBP) completed the acquisition of Oncology assets of Laevoroc Immunology AG for CHF 5.3 million.Helix BioPharma Corp. (TSX:HBP) signed a letter of intent to acquire Oncology assets of Laevoroc Immunology AG on November 12, 2024. Helix BioPharma Corp. (TSX:HBP) entered into a Asset Purchase Agreement to acquire Oncology assets of Laevoroc Immunology AG for CHF 3.7 million on November 28, 2024. As consideration Helix will issue 16.5% of its issued and outstanding shares to Laevoroc. As on November 28, 2024, Helix would be required to issue 8.088553 million common shares based on the Helix's 49,021,536 shares currently issued and outstanding. The companies aim to close definitive agreements before year-end, upon completion of the requisite due diligence. The Transaction is subject to the approval of the Toronto Stock Exchange and certain closing conditions of transactions of a similar nature. The deal is subject to approval of the shareholders of Helix BioPharma Corp. (TSX:HBP).Helix BioPharma anticipates that Transaction will close on or around January 30, 2025 and all shares issuable in connection with the transaction will be subject to a hold period of four months and one day from the date of issuance. As on February 21, 2025, Helix BioPharma announces that its Annual General and Special Meeting for the year ended July 31, 2024, that was to be held by January 31, 2025, has been extended to March 26, 2025 to provide additional time to seek shareholder approval with respect to its proposed asset acquisition from Laevoroc Oncology AG.As on March 26, 2025 , Helix BioPharma shareholders approved the transaction. Helix BioPharma Corp. (TSX:HBP) completed the acquisition of Oncology assets of Laevoroc Immunology AG for CHF 5.3 million on May 20, 2025. In consideration for the transaction, the Company issued 11,555,076 Consideration Shares to Laevoroc Oncology AG.お知らせ • May 15Helix BioPharma Corp. announced that it expects to receive CAD 13 million in fundingHelix BioPharma Corp. announced that it will receive CAD 13 million in funding on May 14, 2025.お知らせ • Mar 13Helix BioPharma Corp. Announces Executive AppointmentsHelix BioPharma Corp. announced the addition of three esteemed experts in oncology and drug development to its executive team. The appointments underscore Helix's commitment to assembling a world-class team to push the limits of proven science and bring life-changing therapies to patients as soon as possible. Thomas Mehrling, MD, PhD Chief Medical Officer (CMO): Dr. Thomas Mehrling (PhD in Pharmacology and MD, University of Frankfurt) brings 20 years of experience shaping the oncology landscape, with previous roles at Takeda, Mundipharma International and Roche. His track record includes the successful introduction of groundbreaking cancer drugs across Europe, with commercial successes nearing USD 1 billion in sales. As Chief Medical Officer, Dr. Mehrling will lead Helix's clinical development strategy, beginning with Tumor Defence BreakerTM L-DOS47--a first-in-class, clinical-stage antibody- enzyme conjugate (AEC) to enhance the effectiveness of today's immune-oncology therapies for the treatment of Non-Small Cell Lung Cancer (NSCLC). Jonathan Davis, PhD Director of ADC Discovery: A leading expert in therapeutic antibodies, Dr. Davis joins Helix as Director of Antibody-Drug Conjugate (ADC) Discovery. With over 15 years of experience spearheading discovery and innovation strategies across diverse therapeutic antibody formats--including monoclonal antibodies (mAbs), multispecifics, and bi-specific ADCs (EMD Serono, Bristol-Myers Squibb, Invenra)--Dr. Davis will play a pivotal role in advancing Helix's ADC portfolio targeting Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CECAM6). As of 2025, Helix is drawing on the latest advancements in design, conjugation, and payload technology to develop bi-specific ADCs and radionuclide drug conjugates (RDCs) for gastrointestinal, gynecological, and other solid tumors. Dr. Davis's expertise will be instrumental in translating these innovations into next-generation, targeted therapies that enhance efficacy while minimizing toxicity. Dr. Davis received his PhD from University of California, San Francisco, and completed his post-doctoral research at Harvard Medical School. Davide Guggi, PhD Chief Technology Officer (CTO): Bringing extensive Chemistry, Manufacturing, and Controls (CMC) expertise, Dr. Guggi joins Helix as Chief Technology Officer. With over a decade of experience guiding the end-to-end development of small molecules and biologics--including mAbs, ADCs, and radio-immuno conjugates--Dr. Guggi has collaborated with more than 20 global biotech firms to drive regulatory success from discovery through to new drug applications (NDA) and biologics license applications (BLA) across the US, EU, and Canada. Prior to his CMC consultancy, he led oncology business units and commercial departments at Mundipharma International and Gilead, and he received his PhD in Pharmaceutical Technology and Biotechnology from the University of Vienna. Dr. Guggi's leadership will be instrumental in ensuring the seamless clinical development of Helix's compounds while optimizing their scalability for later commercialization, positioning the Company for long-term success in bringing innovative cancer therapies to market.お知らせ • Jan 10Helix BioPharma Corp. announced that it has received CAD 3 million in fundingHelix BioPharma Corp. announces that it has closed the private placement of four million common shares of the company at a price of CAD 0.75 per common share for gross proceeds of CAD 3 million. on January 9, 2025. The offering is subject to final approval of the Toronto Stock Exchange. The common shares are subject to a hold period of four months and one day expiring on May 9, 2025, in accordance with applicable securities laws. In connection with the closing, the company paid a cash fee of 105 of gross proceeds raised to an eligible finder.お知らせ • Dec 18Helix BioPharma Corp., Annual General Meeting, Feb 26, 2025Helix BioPharma Corp., Annual General Meeting, Feb 26, 2025.お知らせ • Apr 09Helix BioPharma Corp. announced that it has received CAD 1.915 million in fundingOn April 8, 2024, Helix BioPharma Corp. closed the transaction. The Offering is subject to final approval of the Toronto Stock Exchange. The common shares are subject to a hold period of four months and one day expiring on August 9, 2024 in accordance with applicable securities laws. In connection with the closing. The company paid a cash fee of 10% of gross proceeds equal to CAD 191,500.005 raised to an eligible finder.お知らせ • Mar 30Helix BioPharma Corp. announced that it expects to receive CAD 1.915 million in fundingHelix BioPharma Corp announced private placement financing of 12,766,667 common shares of the company at a price of CAD 0.15 per common share for gross proceeds of CAD 1,915,000 on March 28, 2024. The Offering is subject to customary closing conditions including the receipt of all necessary corporate and regulatory approvals, including the approval of the Toronto Stock Exchange. In connection with the closing, the Company will pay a cash fee of 10% of gross proceeds raised to an eligible finder. The Common Shares will be subject to a hold period of four months and one day from the closing date in accordance with applicable securities laws.お知らせ • Feb 14+ 1 more updateHelix BioPharma Corp. Appoints Praveen Varshney as Chief Financial OfficerHelix BioPharma Corp. announced that Mr. Praveen Varshney has been appointed as Chief Financial Officer (CFO) and Corporate Secretary. Mr. Praveen Varshney has been a principal of Varshney Capital Corp. since 1991. He's also a Founding Director of Pyfera Growth Capital &a Founding Director of Humanitas Smart Planet Fund, both with a social impact focus. Mr. Varshney obtained his UBC Sauder B Comm in 1987 and is a FCPA, FCA. He has been a member of the Vancouver Chapter of EO since 1996 and a founding Director &Charter Member of the Vancouver since 2000. He has been a Co-Founder, Director or Officer of many publicly traded and private companies over the years including Mogo Inc. and Little Kitchen Academy. He"s also on three charity boards such as The Vancouver Foundation and Foundations for Social Change.お知らせ • Nov 08Helix BioPharma Corp., Annual General Meeting, Jan 18, 2024Helix BioPharma Corp., Annual General Meeting, Jan 18, 2024.お知らせ • Oct 13Helix BioPharma Corp. to Present New Preclinical Data on L-DOS47 in Combination with PD1 Checkpoint Inhibitor at the 2023 AACR- NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsHelix BioPharma Corp. announced that the Company will present new preclinical data on L-DOS47 in combination with PD1 checkpoint inhibition at the 2023 AACR- NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in the Hynes Convention Center, Boston, via in person attendance, October 11-15, 2023. During the conference, Helix will highlight the enhanced effects of anti-PD1 immunotherapy when combined with L-DOS47 in an orthotopic Pancreatic tumor model in mice. The drug has already been administered to over 120 patients in the clinic across 4 clinical trials and has been shown to be safe and well tolerated. Additionally, L-DOS47 has also demonstrated promising anti-tumor activity across a range of doses, both as monotherapy and in combination with chemotherapy agents. The Company is open to collaborating with the right partner(s) to explore potential synergies with anti-PD1 and other treatment regimens. Poster Presentation Details: Title: Neutralizing Acidosis with ADC L-DOS47 Urease Immunoconjugate Enhances Response to Anti-PD1 Checkpoint Blockade in A Preclinical Orthotopic Model of Pancreatic Adenocarcinoma. Abstract Number: 35494. Poster Presentation Date and Time: October 13, 12:30 pm - 4:00 pm. Location: Level 2, Exhibit Hall D. Poster Session B, Poster Number: B125.お知らせ • Aug 24Helix BioPharma Corp. announced that it expects to receive CAD 2.998 million in fundingHelix BioPharma Corp. announced a private placement financing of 16,655,557 common shares at a price of CAD 0.18 per common share for proceeds of CAD 2,998,000 on August 22, 2023. The common shares issued pursuant are subject to a statutory hold period of four months. Helix BioPharma Corp. announces that it has closed the first tranche of private placement financing for gross proceeds of CAD 2,998,000.お知らせ • Aug 23Helix BioPharma Corp. Announces Executive ChangesHelix BioPharma Corp. announced appointment of Mr. Janusz Grabski to the board of directors of the Company with an immediate effect. Mr. Grabski is a lawyer specialized in corporate law and real estate law with over twenty years of experience. Mr. Grabski is based in Warsaw, Poland. Alongside the appointment, the Company also announced resignation of Mr. Christopher Maciejewski from the board of directors of the Company due to personal reasons.お知らせ • Nov 18Helix BioPharma Corp., Annual General Meeting, Jan 24, 2023Helix BioPharma Corp., Annual General Meeting, Jan 24, 2023.収支内訳Helix BioPharma の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:HBPC.F 収益、費用、利益 ( )CAD Millions日付収益収益G+A経費研究開発費31 Jan 260-42231 Oct 250-52331 Jul 250-52430 Apr 250-104631 Jan 250-103731 Oct 240-93631 Jul 240-93630 Apr 240-61531 Jan 240-61531 Oct 230-61531 Jul 230-61530 Apr 230-61431 Jan 230-61431 Oct 220-61531 Jul 220-71530 Apr 220-82531 Jan 220-92631 Oct 210-92631 Jul 210-103630 Apr 210-94531 Jan 210-84531 Oct 200-93631 Jul 200-83630 Apr 200-83631 Jan 200-82631 Oct 190-72531 Jul 190-72530 Apr 190-62531 Jan 190-72531 Oct 180-82531 Jul 180-92630 Apr 180-83631 Jan 180-93631 Oct 170-93631 Jul 170-104730 Apr 170-114831 Jan 170-114731 Oct 160-104731 Jul 160-104630 Apr 160-94531 Jan 160-94531 Oct 150-945質の高い収益: HBPC.Fは現在利益が出ていません。利益率の向上: HBPC.Fは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: HBPC.Fは利益を出していないが、過去 5 年間で年間6%の割合で損失を削減してきた。成長の加速: HBPC.Fの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: HBPC.Fは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 43% ) と比較することは困難です。株主資本利益率高いROE: HBPC.Fは現在利益が出ていないため、自己資本利益率 ( -27.32% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 21:30終値2026/05/18 00:00収益2026/01/31年間収益2025/07/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Helix BioPharma Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Ahu DemirNOBLE Capital Markets, Inc.
お知らせ • Nov 24Helix BioPharma Corp., Annual General Meeting, Jan 30, 2026Helix BioPharma Corp., Annual General Meeting, Jan 30, 2026.
お知らせ • Aug 23Helix BioPharma Corp. announced that it has received CAD 1.66675 million in fundingHelix BioPharma Corp. announced that it has closed non-brokered private placement to issue 2,222,333 common shares at a price of CAD 0.75 for gross proceeds of CAD 1,666,749.75 on August 22, 2025. The Offering is subject to final approval of the Toronto Stock Exchange, and the Common Shares are subject to a hold period of four months and one day expiring on December 23, 2025, in accordance with applicable securities laws. In connection with the closing of the Offering, the Company will pay finders’ fees to certain eligible finders.
お知らせ • May 21Helix BioPharma Corp. (TSX:HBP) completed the acquisition of Oncology assets of Laevoroc Immunology AG for CHF 5.3 million.Helix BioPharma Corp. (TSX:HBP) signed a letter of intent to acquire Oncology assets of Laevoroc Immunology AG on November 12, 2024. Helix BioPharma Corp. (TSX:HBP) entered into a Asset Purchase Agreement to acquire Oncology assets of Laevoroc Immunology AG for CHF 3.7 million on November 28, 2024. As consideration Helix will issue 16.5% of its issued and outstanding shares to Laevoroc. As on November 28, 2024, Helix would be required to issue 8.088553 million common shares based on the Helix's 49,021,536 shares currently issued and outstanding. The companies aim to close definitive agreements before year-end, upon completion of the requisite due diligence. The Transaction is subject to the approval of the Toronto Stock Exchange and certain closing conditions of transactions of a similar nature. The deal is subject to approval of the shareholders of Helix BioPharma Corp. (TSX:HBP).Helix BioPharma anticipates that Transaction will close on or around January 30, 2025 and all shares issuable in connection with the transaction will be subject to a hold period of four months and one day from the date of issuance. As on February 21, 2025, Helix BioPharma announces that its Annual General and Special Meeting for the year ended July 31, 2024, that was to be held by January 31, 2025, has been extended to March 26, 2025 to provide additional time to seek shareholder approval with respect to its proposed asset acquisition from Laevoroc Oncology AG.As on March 26, 2025 , Helix BioPharma shareholders approved the transaction. Helix BioPharma Corp. (TSX:HBP) completed the acquisition of Oncology assets of Laevoroc Immunology AG for CHF 5.3 million on May 20, 2025. In consideration for the transaction, the Company issued 11,555,076 Consideration Shares to Laevoroc Oncology AG.
お知らせ • May 15Helix BioPharma Corp. announced that it expects to receive CAD 13 million in fundingHelix BioPharma Corp. announced that it will receive CAD 13 million in funding on May 14, 2025.
お知らせ • Mar 13Helix BioPharma Corp. Announces Executive AppointmentsHelix BioPharma Corp. announced the addition of three esteemed experts in oncology and drug development to its executive team. The appointments underscore Helix's commitment to assembling a world-class team to push the limits of proven science and bring life-changing therapies to patients as soon as possible. Thomas Mehrling, MD, PhD Chief Medical Officer (CMO): Dr. Thomas Mehrling (PhD in Pharmacology and MD, University of Frankfurt) brings 20 years of experience shaping the oncology landscape, with previous roles at Takeda, Mundipharma International and Roche. His track record includes the successful introduction of groundbreaking cancer drugs across Europe, with commercial successes nearing USD 1 billion in sales. As Chief Medical Officer, Dr. Mehrling will lead Helix's clinical development strategy, beginning with Tumor Defence BreakerTM L-DOS47--a first-in-class, clinical-stage antibody- enzyme conjugate (AEC) to enhance the effectiveness of today's immune-oncology therapies for the treatment of Non-Small Cell Lung Cancer (NSCLC). Jonathan Davis, PhD Director of ADC Discovery: A leading expert in therapeutic antibodies, Dr. Davis joins Helix as Director of Antibody-Drug Conjugate (ADC) Discovery. With over 15 years of experience spearheading discovery and innovation strategies across diverse therapeutic antibody formats--including monoclonal antibodies (mAbs), multispecifics, and bi-specific ADCs (EMD Serono, Bristol-Myers Squibb, Invenra)--Dr. Davis will play a pivotal role in advancing Helix's ADC portfolio targeting Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CECAM6). As of 2025, Helix is drawing on the latest advancements in design, conjugation, and payload technology to develop bi-specific ADCs and radionuclide drug conjugates (RDCs) for gastrointestinal, gynecological, and other solid tumors. Dr. Davis's expertise will be instrumental in translating these innovations into next-generation, targeted therapies that enhance efficacy while minimizing toxicity. Dr. Davis received his PhD from University of California, San Francisco, and completed his post-doctoral research at Harvard Medical School. Davide Guggi, PhD Chief Technology Officer (CTO): Bringing extensive Chemistry, Manufacturing, and Controls (CMC) expertise, Dr. Guggi joins Helix as Chief Technology Officer. With over a decade of experience guiding the end-to-end development of small molecules and biologics--including mAbs, ADCs, and radio-immuno conjugates--Dr. Guggi has collaborated with more than 20 global biotech firms to drive regulatory success from discovery through to new drug applications (NDA) and biologics license applications (BLA) across the US, EU, and Canada. Prior to his CMC consultancy, he led oncology business units and commercial departments at Mundipharma International and Gilead, and he received his PhD in Pharmaceutical Technology and Biotechnology from the University of Vienna. Dr. Guggi's leadership will be instrumental in ensuring the seamless clinical development of Helix's compounds while optimizing their scalability for later commercialization, positioning the Company for long-term success in bringing innovative cancer therapies to market.
お知らせ • Jan 10Helix BioPharma Corp. announced that it has received CAD 3 million in fundingHelix BioPharma Corp. announces that it has closed the private placement of four million common shares of the company at a price of CAD 0.75 per common share for gross proceeds of CAD 3 million. on January 9, 2025. The offering is subject to final approval of the Toronto Stock Exchange. The common shares are subject to a hold period of four months and one day expiring on May 9, 2025, in accordance with applicable securities laws. In connection with the closing, the company paid a cash fee of 105 of gross proceeds raised to an eligible finder.
お知らせ • Dec 18Helix BioPharma Corp., Annual General Meeting, Feb 26, 2025Helix BioPharma Corp., Annual General Meeting, Feb 26, 2025.
お知らせ • Apr 09Helix BioPharma Corp. announced that it has received CAD 1.915 million in fundingOn April 8, 2024, Helix BioPharma Corp. closed the transaction. The Offering is subject to final approval of the Toronto Stock Exchange. The common shares are subject to a hold period of four months and one day expiring on August 9, 2024 in accordance with applicable securities laws. In connection with the closing. The company paid a cash fee of 10% of gross proceeds equal to CAD 191,500.005 raised to an eligible finder.
お知らせ • Mar 30Helix BioPharma Corp. announced that it expects to receive CAD 1.915 million in fundingHelix BioPharma Corp announced private placement financing of 12,766,667 common shares of the company at a price of CAD 0.15 per common share for gross proceeds of CAD 1,915,000 on March 28, 2024. The Offering is subject to customary closing conditions including the receipt of all necessary corporate and regulatory approvals, including the approval of the Toronto Stock Exchange. In connection with the closing, the Company will pay a cash fee of 10% of gross proceeds raised to an eligible finder. The Common Shares will be subject to a hold period of four months and one day from the closing date in accordance with applicable securities laws.
お知らせ • Feb 14+ 1 more updateHelix BioPharma Corp. Appoints Praveen Varshney as Chief Financial OfficerHelix BioPharma Corp. announced that Mr. Praveen Varshney has been appointed as Chief Financial Officer (CFO) and Corporate Secretary. Mr. Praveen Varshney has been a principal of Varshney Capital Corp. since 1991. He's also a Founding Director of Pyfera Growth Capital &a Founding Director of Humanitas Smart Planet Fund, both with a social impact focus. Mr. Varshney obtained his UBC Sauder B Comm in 1987 and is a FCPA, FCA. He has been a member of the Vancouver Chapter of EO since 1996 and a founding Director &Charter Member of the Vancouver since 2000. He has been a Co-Founder, Director or Officer of many publicly traded and private companies over the years including Mogo Inc. and Little Kitchen Academy. He"s also on three charity boards such as The Vancouver Foundation and Foundations for Social Change.
お知らせ • Nov 08Helix BioPharma Corp., Annual General Meeting, Jan 18, 2024Helix BioPharma Corp., Annual General Meeting, Jan 18, 2024.
お知らせ • Oct 13Helix BioPharma Corp. to Present New Preclinical Data on L-DOS47 in Combination with PD1 Checkpoint Inhibitor at the 2023 AACR- NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsHelix BioPharma Corp. announced that the Company will present new preclinical data on L-DOS47 in combination with PD1 checkpoint inhibition at the 2023 AACR- NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in the Hynes Convention Center, Boston, via in person attendance, October 11-15, 2023. During the conference, Helix will highlight the enhanced effects of anti-PD1 immunotherapy when combined with L-DOS47 in an orthotopic Pancreatic tumor model in mice. The drug has already been administered to over 120 patients in the clinic across 4 clinical trials and has been shown to be safe and well tolerated. Additionally, L-DOS47 has also demonstrated promising anti-tumor activity across a range of doses, both as monotherapy and in combination with chemotherapy agents. The Company is open to collaborating with the right partner(s) to explore potential synergies with anti-PD1 and other treatment regimens. Poster Presentation Details: Title: Neutralizing Acidosis with ADC L-DOS47 Urease Immunoconjugate Enhances Response to Anti-PD1 Checkpoint Blockade in A Preclinical Orthotopic Model of Pancreatic Adenocarcinoma. Abstract Number: 35494. Poster Presentation Date and Time: October 13, 12:30 pm - 4:00 pm. Location: Level 2, Exhibit Hall D. Poster Session B, Poster Number: B125.
お知らせ • Aug 24Helix BioPharma Corp. announced that it expects to receive CAD 2.998 million in fundingHelix BioPharma Corp. announced a private placement financing of 16,655,557 common shares at a price of CAD 0.18 per common share for proceeds of CAD 2,998,000 on August 22, 2023. The common shares issued pursuant are subject to a statutory hold period of four months. Helix BioPharma Corp. announces that it has closed the first tranche of private placement financing for gross proceeds of CAD 2,998,000.
お知らせ • Aug 23Helix BioPharma Corp. Announces Executive ChangesHelix BioPharma Corp. announced appointment of Mr. Janusz Grabski to the board of directors of the Company with an immediate effect. Mr. Grabski is a lawyer specialized in corporate law and real estate law with over twenty years of experience. Mr. Grabski is based in Warsaw, Poland. Alongside the appointment, the Company also announced resignation of Mr. Christopher Maciejewski from the board of directors of the Company due to personal reasons.
お知らせ • Nov 18Helix BioPharma Corp., Annual General Meeting, Jan 24, 2023Helix BioPharma Corp., Annual General Meeting, Jan 24, 2023.